JP2017527598A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527598A5
JP2017527598A5 JP2017514842A JP2017514842A JP2017527598A5 JP 2017527598 A5 JP2017527598 A5 JP 2017527598A5 JP 2017514842 A JP2017514842 A JP 2017514842A JP 2017514842 A JP2017514842 A JP 2017514842A JP 2017527598 A5 JP2017527598 A5 JP 2017527598A5
Authority
JP
Japan
Prior art keywords
injury
compound according
disease
alkyl
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017514842A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527598A (ja
JP6596080B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/050814 external-priority patent/WO2016044667A1/en
Publication of JP2017527598A publication Critical patent/JP2017527598A/ja
Publication of JP2017527598A5 publication Critical patent/JP2017527598A5/ja
Application granted granted Critical
Publication of JP6596080B2 publication Critical patent/JP6596080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017514842A 2014-09-17 2015-09-17 化合物および方法 Active JP6596080B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051735P 2014-09-17 2014-09-17
US62/051,735 2014-09-17
US201462052283P 2014-09-18 2014-09-18
US62/052,283 2014-09-18
PCT/US2015/050814 WO2016044667A1 (en) 2014-09-17 2015-09-17 Compounds and methods

Publications (3)

Publication Number Publication Date
JP2017527598A JP2017527598A (ja) 2017-09-21
JP2017527598A5 true JP2017527598A5 (https=) 2018-10-18
JP6596080B2 JP6596080B2 (ja) 2019-10-23

Family

ID=55533880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017514842A Active JP6596080B2 (ja) 2014-09-17 2015-09-17 化合物および方法

Country Status (14)

Country Link
US (2) US10150774B2 (https=)
EP (2) EP3193878B1 (https=)
JP (1) JP6596080B2 (https=)
KR (1) KR102332957B1 (https=)
CN (1) CN107106563B (https=)
AU (1) AU2015317527B2 (https=)
BR (1) BR112017005533B1 (https=)
CA (1) CA2961212C (https=)
ES (2) ES2857567T3 (https=)
HK (1) HK1243342A1 (https=)
IL (2) IL292225B2 (https=)
MX (1) MX385382B (https=)
RU (1) RU2711442C2 (https=)
WO (1) WO2016044667A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
AU2019275453B2 (en) * 2018-05-25 2023-12-21 Intra-Cellular Therapies, Inc. Organic compounds
CN113194955A (zh) * 2018-10-21 2021-07-30 细胞内治疗公司 新用途
US12396992B2 (en) 2019-01-07 2025-08-26 Intra-Cellular Therapies, Inc. Organic compounds
WO2020210614A1 (en) * 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Organic compounds
AU2020343329C1 (en) * 2019-09-03 2026-02-12 Intra-Cellular Therapies, Inc. Methods of treatment
EP4025202A4 (en) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032638B2 (ja) 1976-09-01 1985-07-29 武田薬品工業株式会社 ３−アミノピラゾロ〔３，４−ｄ〕ピリミジン誘導体
EP0077372A1 (de) 1981-04-22 1983-04-27 Byk Gulden Lomberg Chemische Fabrik GmbH NEUE PYRAZOLO(3,4-d)PYRIMIDINE, VERFAHREN ZU DEREN HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL
US4469868A (en) 1982-05-24 1984-09-04 Warner-Lambert Company Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
US4603203A (en) 1983-12-14 1986-07-29 Takeda Chemical Industries, Ltd. 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
ZA914727B (en) 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
WO1994019351A1 (en) 1993-02-26 1994-09-01 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
EP0977756A1 (en) * 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en) 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
DE69943144D1 (de) 1998-03-31 2011-03-03 Kyowa Hakko Kirin Co Ltd Stickstoffenthaltende heterocyclische verbindungen
US6133273A (en) 1998-05-08 2000-10-17 American Home Products Corporation Pyrazolopyrimidine-2,4-dione sulfonamides
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
AU5636900A (en) 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
DE19931206A1 (de) 1999-07-07 2001-01-11 Stief Christian Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
JP2003510325A (ja) 1999-09-30 2003-03-18 ニューロジェン・コーポレーション ある種のアルキレンジアミン−置換ピラゾロ［１，５−ａ］−１，５−ピリミジン及びピラゾロ［１，５−ａ］−１，３，５−トリアジン
AP2002002455A0 (en) 1999-10-11 2002-06-30 Pfizer 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
IL139073A0 (en) 1999-10-21 2001-11-25 Pfizer Treatment of neuropathy
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
JP2004500425A (ja) 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
EP1372656B1 (en) 2001-03-16 2005-06-22 Pfizer Limited Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
WO2003020724A1 (en) 2001-08-28 2003-03-13 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
EP1575916B1 (en) * 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
CA2465893A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
AU2003219770B2 (en) 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
IL163575A0 (en) 2002-02-21 2005-12-18 Univ Rockefeller Compositions and method for regulation of calcium-dependent signalling in brain
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
EP1613747A1 (en) 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
US20050113379A1 (en) 2003-09-05 2005-05-26 Ping Ge Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
US8273750B2 (en) 2005-06-06 2012-09-25 Takeda Pharmaceutical Company Limited Organic compounds
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
JP5453086B2 (ja) 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US20070286890A1 (en) 2006-06-07 2007-12-13 John Garnett Walt Eyelash applicator and method
JP2010509399A (ja) * 2006-11-13 2010-03-25 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
PT2152712E (pt) * 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
AU2008335811B2 (en) 2007-12-06 2012-05-17 Intra-Cellular Therapies, Inc. Organic compounds
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
MX2011005936A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
JP5989993B2 (ja) 2008-12-06 2016-09-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
KR20110098732A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
AU2009322904A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
JP2012518685A (ja) * 2009-02-25 2012-08-16 イントラ−セルラー・セラピーズ・インコーポレイテッド 眼障害のためのｐｄｅ１阻害剤
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP2013507360A (ja) 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
EP2560676B8 (en) 2010-04-22 2016-10-12 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
CA2906640C (en) * 2013-03-15 2021-07-20 Intra-Cellular Therapies, Inc. Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
WO2016022893A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
CN104570148B (zh) * 2014-12-29 2015-09-02 河海大学 涉水结构物渗漏无热源光纤定位定向系统及监测方法

Similar Documents

Publication Publication Date Title
JP2017527598A5 (https=)
KR102821964B1 (ko) 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법
CN107089985B (zh) 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物
US12552777B2 (en) Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
MX2022016276A (es) Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson.
PH12015500294B1 (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2017127430A1 (en) Irak4 inhibiting agents
CA2895426A1 (en) Bet-protein-inhibiting dihydroquinoxalinones
JP2022531088A (ja) Ｊａｋ阻害剤としての置換ピロロピリジン
WO2019090143A1 (en) Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same
CN105085482B (zh) 取代的哌嗪化合物及其使用方法和用途
IL285708B1 (en) Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
PH12021552375A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN105294554B (zh) 苯基哌嗪衍生物及其使用方法和用途
CN105461635B (zh) 苯基哌嗪衍生物及其使用方法和用途
WO2025008732A1 (en) Novel compounds as modulators of il17
JP2021535924A (ja) 新規なチアゾール誘導体及びその薬学的に許容される塩
JP2017514867A5 (https=)
CN105085491B (zh) 取代的吲哚化合物及其使用方法和用途
CN106279153B (zh) 取代的吲哚化合物及其使用方法和用途
CN109912514B (zh) (2-杂芳基胺基苯基)氮杂环衍生物及其用途
CN106065018B (zh) 取代的吲哚化合物及其使用方法和用途
CN108409729B (zh) 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108069937B (zh) 苯基哌啶衍生物及其使用方法和用途
IL325020A (en) Neuroplasticity modulators for the treatment of pain, itching, and nerve injury